Characteristics, healthcare utilization, and outcomes of patients with HER2-low breast cancer.

Devon K CheckBradford E JacksonKatherine E Reeder-HayesMichaela A DinanEleanor FahertyJackie KwongSandhya MehtaLisa SpeesStephanie B WheelerLauren E WilsonClara Lam

Published in: Breast cancer research and treatment (2023)

New treatment options for HER2-low breast cancer may have potential for significant impact at the population level particularly for patients with stage IV disease. In light of racial differences between HER2-low and IHC 0 patients observed in our cohort, research- and practice-based efforts to ensure equitable adoption of new treatment guidelines for patients with HER2-low metastatic breast cancer will be essential.

Keyphrases

healthcare
metastatic breast cancer
end stage renal disease
newly diagnosed
primary care
ejection fraction
quality improvement
prognostic factors
skeletal muscle
insulin resistance
patient reported outcomes
replacement therapy
breast cancer risk